Literature DB >> 8984936

Antinuclear antibody determination in a routine laboratory.

T E Feltkamp1.   

Abstract

Pitfalls in the method for demonstrating antinuclear antibodies (ANA) by the indirect immunofluorescence technique are described and the use of international standard preparations outlined. Determination of the optimal border dilution dividing positive from negative results is discussed. Each laboratory is a unique setting; it must define its own method, which should rarely be changed. One should not rely on copying methods from other laboratories or commercial firms, but the reproducibility of the nuclear substrate, the conjugate, and other variables should be controlled daily by the use of a control serum which has been related to the WHO standard preparation for ANA of the homogeneous type. Since many sera contain mixtures of different ANA, the results of routine tests are best expressed in titres or expressions of the intensity of fluorescence. The ANA test using the immunofluorescence technique should be used as a screening method for other tests allowing a more defined interpretation of the ANA. Each laboratory should individually determine the border between positive and negative results. Therefore about 200 sera from local healthy controls equally distributed over sex and age, and 100 sera from local patients with definite SLE should be tested. Since the local clinicians should become acquainted with this border it should rarely be changed. Finally each laboratory should participate regularly in national and international quality control rounds, where sera known to be difficult to interpret are tested. The judgment of the organisers of these rounds should stimulate improvements in the participating laboratories.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984936      PMCID: PMC1010287          DOI: 10.1136/ard.55.10.723

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  A serum factor in lupus erythematosus with affinity for tissue nuclei.

Authors:  E J HOLBOROW; D M WEIR; G D JOHNSON
Journal:  Br Med J       Date:  1957-09-28

2.  Standards for ANA and anti-DNA.

Authors:  T E Feltkamp
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Standardisation of the quantitative determination of antinuclear antibodies (ANAs) with a homogeneous pattern.

Authors:  T E Feltkamp; F Klein; M B Janssens
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

4.  Quantitative studies of immunofluorescent staining. I. Analyses of mixed immunofluorescence.

Authors:  E H Beutner; E J Holborow; G D Johnson
Journal:  Immunology       Date:  1967-03       Impact factor: 7.397

5.  Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method.

Authors:  T H The; T E Feltkamp
Journal:  Immunology       Date:  1970-06       Impact factor: 7.397

6.  Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors.

Authors:  M J Fritzler; J D Pauls; T D Kinsella; T J Bowen
Journal:  Clin Immunol Immunopathol       Date:  1985-07

7.  Dissociation of DNA/anti-DNA complexes at high pH.

Authors:  E R de Groot; M C Lamers; L A Aarden; R J Smeenk; C J van Oss
Journal:  Immunol Commun       Date:  1980

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

9.  Clinical application of a test for lupus globulin-nucleohistone interaction using fluorescent antibody.

Authors:  G J FRIOU
Journal:  Yale J Biol Med       Date:  1958-09
  9 in total
  3 in total

Review 1.  Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice.

Authors:  Biman Saikia; Amit Rawat; Pandiarajan Vignesh
Journal:  Indian J Pediatr       Date:  2015-12-03       Impact factor: 5.319

2.  Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited.

Authors:  Yashwant Kumar; Alka Bhatia; Ranjana Walker Minz
Journal:  Diagn Pathol       Date:  2009-01-02       Impact factor: 2.644

Review 3.  The use and abuse of commercial kits used to detect autoantibodies.

Authors:  Marvin J Fritzler; Allan Wiik; Mark L Fritzler; Susan G Barr
Journal:  Arthritis Res Ther       Date:  2003-06-09       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.